Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

October 24, 2012

Primary Completion Date

September 8, 2019

Study Completion Date

September 8, 2019

Conditions
Kidney Cancer
Interventions
DRUG

Pazopanib

800 mg by mouth daily in 4 week study cycle.

DRUG

Temsirolimus

25 mg by vein infused over 30-60 minutes every week in 4 week study cycle.

BEHAVIORAL

Quality of Life Assessment

Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.

DRUG

Benadryl

25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER